| Donna Alford Wilkins, MD | |
|
Delaware County Health Department, 125 North Mulberry Street, Muncie, IN 47305-1718 | |
| (765) 587-0670 | |
| (765) 747-7747 |
| Full Name | Donna Alford Wilkins |
|---|---|
| Gender | Female |
| Speciality | Public Health Or Welfare |
| Location | Delaware County Health Department, Muncie, Indiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922072511 | NPI | - | NPPES |
| 000000304598 | Other | IN | ANTHEM BC/BS |
| 300039005 | Medicaid | IN |
| Mailing Address | Practice Location Address |
|---|---|
| Donna Alford Wilkins, MD 125 N Mulberry St, Muncie, IN 47305-1718 Ph: (765) 587-0670 | Donna Alford Wilkins, MD Delaware County Health Department, 125 North Mulberry Street, Muncie, IN 47305-1718 Ph: (765) 587-0670 |
News Archive
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.
The Foundation Stiftelsen Kristian Gerhard Jebsen has donated NOK 22.5 million to a Norwegian national center for the fight against Alzheimer's disease. The grant was made public on 26 February.
Nine facilities in the northern California region have been named Centers of Excellence in accelerated partial breast irradiation (APBI) for their use of the SAVI® applicator, an advanced therapy for breast cancer as part of breast conservation therapy. The SAVI applicator can provide important advantages for women with early-stage breast cancer.
Scientists have developed a wearable device that can detect the early onset of COVID-19 in real-time by analyzing the aberrant changes in physiological parameters caused by SARS-CoV-2 infection.
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of Warwick, the Baker Institute and Monash University.
› Verified 4 days ago